Theralase Technologies Inc. (FRA:TTX)

Market Cap	33.81M -3.0%
Revenue (ttm)	533.05K -9.6%
Net Income	-2.29M
EPS	-0.01
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	0.1070
Previous Close	0.1100
Day's Range	0.1070 - 0.1070
52-Week Range	0.0805 - 0.2320
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 2, 2026

About Theralase Technologies

Theralase Technologies Inc., a clinical stage pharmaceutical company, engages in the research, development, and commercialization of energy activated small molecules and associated drug formulations in Canada, the United States, and internationally. The company operates in two segments, Drug Division and Device Division. It engages in the research and development of Rutherrin, an injectable form of Ruvidar for the treatment of glio blastoma multiforme, a form of brain cancer, non-small cell lung cancer, pancreatic cancer, colorectal cancer, and...

• Industry: Electromedical and Electrotherapeutic Apparatus
• CEO: Roger Dumoulin-White
• Employees: 20
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: TTX

Financial Performance

In 2025, Theralase Technologies's revenue was 816,468, a decrease of -20.99% compared to the previous year's 1.03 million. Losses were -4.12 million, -3.18% less than in 2024.

Financial numbers in CAD

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Aug 27, 2026

Data Sources Report a data error